Evidence map›Paper›PMID 31929548›Full record

ArticlePloS one2020

LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanisms.

Eduardo Valli, Robin L Baudier, Amanda J Harriett, Elizabeth B Norton

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Recent advances in enterotoxin vaccine adjuvants.Current opinion in immunology · 2023
    Review
  10. Article
  11. Mucosal vaccines - fortifying the frontiers.Nature reviews. Immunology · 2022
    Review
  12. EnterotoxigenicInfection and immunity · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eduardo ValliDepartment of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America.
Robin L BaudierDepartment of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America.ORCID 0000-0002-3912-8891
Amanda J HarriettDepartment of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America.ORCID 0000-0002-7858-1592
Elizabeth B NortonDepartment of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America.ORCID 0000-0002-8426-3515
Tulane University · US

Funding

Development of Novel Adjuvants LTA and LTA1R01AI114697 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI NORTON, ELIZABETH B · 2015 to 2019
$2.1M
Mechanisms of dmLT AdjuvantR56AI143937 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI NORTON, ELIZABETH B · 2020 to 2020
$261k
NIAID NIH HHS R01 AI114697NIAID NIH HHS R56 AI143937
6 · The paper itself

Abstract

Enterotoxin-based proteins are powerful manipulators of mucosal immunity. The A1 domain of heat-labile enterotoxin from E. coli, or LTA1, is a newer adjuvant from this family under investigation for intranasal vaccines. Although LTA1 has been examined in mouse vaccination studies, its ability to directly stimulate immune cells compared to related adjuvant proteins has not been well explored. Here, we perform the first rigorous examination of LTA1's effect on antigen presenting cells (APC) using a human monocyte cell line THP-1. To better understand LTA1's stimulatory effects, we compared it to dmLT, or LT-R192G/L211A, a related AB5 adjuvant in clinical trials for oral or parenteral vaccines. LTA1 and dmLT both activated APCs to upregulate MHC-II (HLA-DR), CD86, cytokine secretion (e.g., IL-1β) and inflammasome activation. The effect of LTA1 on surface marker changes (e.g., MHC-II) was highly dose-dependent whereas dmLT exhibited high MHC-II expression regardless of dose. In contrast, cytokine secretion profiles were similar and dose-dependent after both LTA1 and dmLT treatment. Cellular activation by LTA1 was independent of ganglioside binding, as pre-treatment with purified GM1 blocked the effect of dmLT but not LTA1. Unexpectedly, while activation of the inflammasome and cytokine secretion by LTA1 or dmLT was blocked by the protein kinase A inhibitor H89 (similar to previous reports), these responses were not inhibited by a more specific PKA peptide inhibitor or antagonist; thus Indicating that a novel and unknown mechanism is responsible for inflammasome activation and cytokine secretion by LT proteins. Lastly, LTA1 stimulated a similar cytokine profile in primary human monocytes as it did in THP1 cells, including IL-1β, IL-6, IL-8, MIP-1α, MIP-1β, and TNFα. Thus, we report that LTA1 protein programs a dendritic cell-like phenotype in APCs similar to dmLT in a mechanism that is independent of PKA activation and GM1 binding and entry.

Indexed as

Adjuvants, ImmunologicAntigen-Presenting CellsCell LineCell Membrane PermeabilityCells, CulturedCyclic AMP-Dependent Protein KinasesCytokinesEnterotoxinsHumansInflammasomesLipopolysaccharidesMonocytesTeichoic AcidsTHP-1 CellsAdjuvants, ImmunologicCyclic AMP-Dependent Protein KinasesCytokinesEnterotoxinsInflammasomesLipopolysaccharideslipoteichoic acidTeichoic Acids

Identifiers

PMID31929548
PMCPMC6957164
OpenAlexW3000648910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.